A phase 2b Randomized, Double-blind, Placebo-controlled, Parallel-Group Study to Assess Efficacy and Safety of Verekitug (UPB-101) in Participants with Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
Study Sponsor: Upstream Bio, Inc.
Location: HealthPartners Specialty Center
Phase of Study: Phase II
Purpose of study: This study is looking at how effective a new drug called Verekitug is in helping patients with chronic obstructive pulmonary disease (COPD) to breathe better. It is a blinded, randomized, placebo-controlled study, which means that there is 66% chance participants will get Verekitug and a 33% chance they will get a control drug with no active ingredients, and neither the study doctor nor the patient will know until the end of the study what they got. Study participation lasts about 18 to 24 months and involves up to 19 on-site visits and 12 phone visits.
Inclusion Criteria:
To qualify, you must be between the ages of 40 and 85, have moderate-to-severe COPD, and currently be on medication such as Trelegy Ellipta or Spiriva + Pulmicort to treat this condition. (There are many other medications that qualify.) You also must have had one hospitalization for COPD or have had two flare-ups requiring steroids and antibiotics in the past year.
Exclusion Criteria:
You may not be eligible if you have had lung cancer in the past or have had any kind of non-skin cancer in the past 5 years, have severe heart failure, or have had a recent heart attack or stroke.
There are other inclusion and exclusion criteria, so please contact the study team for more information.
Study Contact:
Amanda Gillesby
(952) 967-9369
Amanda.D.Gillesby@HealthPartners.Com
ANCHOR asthma clinical trial
Study sponsor: AstraZeneca Pharmaceuticals LP
Location: Enrolled participants do not need to travel.
Purpose of study:
Purpose of study: The ANCHOR asthma clinical trial is being done by AstraZeneca to assess how well AIRSUPRA reduces severe asthma attacks in adults. AIRSUPRA is an FDA approved rescue inhaler that combines two common asthma medicines (albuterol and budesonide) into a single inhaler that will help treat symptoms and help prevent asthma attacks. Albuterol helps to relax the smooth muscles of the airways, causing the airways to widen, leading to easier breathing. Budesonide helps to decrease inflammation in the lungs.
Recruitment for this study has concluded. If you are a current participant, you can contact the study by phone at 952-967-6910 or email at AnchorStudy@HealthPartners.com
Study Contact:
(952) 967-6910
AnchorStudy@HealthPartners.com
